Courses

In this module, Van Karlyle Morris, MD, along with Scott Kopetz, MD, PhD, course chair, will highlight current strategies for targeting MAPK signaling in colorectal cancer (CRC). Recent clinical trial data for BRAF-mutated CRC, particularly various survival outcomes data, will be reviewed and clinical relevance debated throughout the interview. The emerging role of immunotherapy will also be evaluated. Upon completion ...
View Course

In this module, Rona Yaeger, MD, along with Scott Kopetz, MD, PhD, course chair, will first cover strategies for modulating toxicity of targeted therapies for BRAF V600E colorectal cancer (CRC). The expert faculty will discuss best practices for improving the therapeutic index to target non-V600 BRAF mutant CRC through a discussion-based format. Recent clinical trial data, including that of the ...
View Course

In this module, Jamie Faber, PA-C and Tracy Trevino, BSN, RN, along with Scott Kopetz, MD, PhD, course chair, will highlight the role of the interprofessional team in administering optimal patient education and promoting compliance. Practical recommendations for addressing disparities in patient care will also be provided. Further, the expert faculty will discuss side effect management and best practices for ...
View Course

This CME/CE activity will highlight recent data for the treatment and management of acute leukemia, including information presented at the American Society of Hematology Annual Meeting in Orlando, Florida. The expert faculty, chaired by Eytan M. Stein, MD, will first discuss the pathophysiology of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), reviewing diagnostic criteria and comorbidities. Current clinical ...
View Course

This continuing education program will highlight recent advances in the treatment and management of breast cancer, with a focus on HER2-targeted therapy. The expert faculty will review the current treatment landscape for both early stage and metastatic breast cancer. Recent clinical trial data of emerged and emerging agents, particularly best practices for optimizing HER2-targeted therapy continuing into the adjuvant setting, ...
View Course

This CME/CE activity will provide clinicians with an overview of the novel treatment strategies and management techniques for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The three expert faculty will review the pathophysiology of AML and ALL, including the methods used for diagnosing disease and monitoring treatment. An analysis of the latest data for current and ...
View Course

This CME/CE activity will highlight recent data for the treatment and management of multiple myeloma (MM), including information presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. The expert faculty, chaired by C. Ola Landgren, MD, PhD, will first discuss the pathophysiology of multiple myeloma, reviewing the skeletal, renal, hematologic and neurologic processes in a ...
View Course

This CME/CNE program will provide a comprehensive update of best practices for treating and managing patients with acute lymphoblastic leukemia (ALL). The expert faculty will outline molecular mutations and patient prognosis, including the t-acute lymphoblastic leukemia and the b-acute lymphoblastic leukemia subtypes. Current clinical trial data will be analyzed, particularly recent breakthroughs in the care of adults with ALL. The ...
View Course

This CME/CNE activity will review recent advances in patients with Bladder Cancer as presented at the American Society of Clinical Oncology- Genitourinary Cancers (ASCO GU) 2019 Symposium in San Francisco, CA. Dr. Richard Lee will inform on clinical decision making for patients with bladder cancer by reviewing the science and tumor microenvironment. He will also discuss the latest clinical treatment options for ...
View Course

This CME/CNE program will provide learners with an update regarding treatment and management of patients with hepatocellular carcinoma (HCC) through an interactive panel format. The expert faculty will first set the stage for modern day HCC care, reviewing the science, prevalence and current treatment guidelines. Recent clinical trial data of first line, second line and combination therapies will be analyzed ...
View Course